Abstract:Objective: To evaluate the efficacy and safety of injectable gatifloxacin. Methods; In this multicenter, single-blind, randomized comparative study, patients with infection of lower respiratory tract and urinary tract were allocated randomly to gatifloxacin group or levofloxacin group. In each group patients were given gatifloxacin or levofloxacin intrevenously for 3-5 d followed by oral formulation. Results: (1)The clinical effective rates (gatifloxacin vs. levofloxacin) were 92.4%(110/119) vs. 91.2%(114/ 125), being 94.296(65/69) vs. 90.296(65/72) for lower respiratory tract infections and 90.0% (45/50) vs. 92.5%(42/72) for urinary tract infections, respectively, there was no statistically significant difference between the two groups; (2)The total bacterial eradication rates were 94.0% (78/83) vs. 88.0% (81/92), being 89.2% (33/37) vs. 92.9% (39/42) for urinary tract infections, there was no statistically significant difference between the two groups; however, the bacterial eradication rate of gatifloxacin (97.8% , 45/46) was higher than that of levofloxacin (84. 3% , 43/51) in lower respiratory tract infections, the difference was statistically significant. (3)Drug-related adverse effects were 29.9% (38/127) in gatifloxacin group, higher than that in levofloxacin group 10.1% (13/129). This is due to more patients with phlebitis and gastrointestinal symptoms in gatifloxacin group than those in levofloxacin group. These drug-related events could be alleviated by slowing down the speed of infusion; the adverse effects of both groups were mild and tolerable, no discontinuation of treatment due to adverse reaction. Drug-related abnormal laboratory findings oc- carred in gatifloxacin group and levefloxacin group were 24. 8% (30 /121) and 22. 1 % (27 /112) respectively. All were mild and transient, and there was no statistically significant difference between the two groups. Conclusions: Gatifloxacin given intravenously used as initial therapy in infectious patients with systemic clinical manifestations and followed by oral administration for the completion of therapy may get satisfactory results. The clinical efficacy of gatifloxacin is as good as that of levofloxacin. The adverse reaction rate of gatifloxacin was slightly higher than that of levofloxacin, but all the reactions are mild and tolerable.

Clinical study of lomefloxacin compared with ofloxacin in the treatment of bacterial infections

A Multi-Center, Randomized, Controlled, Double Blind and Double Dummy Clinical Trial of Antofloxacin Hydrochloride Tablet Versus Levofloxacin Tablet for the Treatment of Acute Bacterial Infections

A Randomized Controlled Clinical Study on Levofloxacin Versus Ciprofloxacin in the Treatment of Bacterial Infections

A Multicenter, Single-Blind, Randomized Comparison of Sequential Therapy of Gatifloxacin Versus Levofloxacin in the Treatment of Bacterial Infections

Clinical evaluation of pazufloxacin and levofloxacin in the treatment of bacterial infections

Influences of Levofloxacin Salts on the Metabolism of Escherichia Coli by Microcalorimetry

Randomized Controlled Clinical Trial of Moxifloxacin Versus Levofloxacin Injection in the Treatment of Community Acquired Pneumonia

Double-blind Randomized Controlled Clinical Trial on Gatifloxacin Versus Levofloxacin Injection for Treating Acute Bacterial Infections

A randomized comparative study of gatifloxacin and ciprofloxacin in the treatment of bacterial infections

A Double-Blind, Randomized Controlled Clinical Study:Gatifloxacin Vs Levofloxacin in Treatment of 98 Patients with Urinary Tract Infections

A Randomized, Controlled, Multicenter Clinical Trial To Evaluate The Efficacy And Safety Of Oral Sitafloxacin Versus Moxifloxacin In Adult Patients With Community-Acquired Pneumonia

Effect of mercifloxacin and levofloxacin on urinary tract infection

A Phase Ii Study of Antofloxacin Hydrochloride, A Novel Fluoroquinolone, for the Treatment of Acute Bacterial Infections

A clinical randomized controlled trial of pazufloxacin injection in treatment of bacterial infection in 111 patients

Clinical evaluation of oral levofloxacin 500 mg once-daily dosage for treatment of lower respiratory tract infections and urinary tract infections: a prospective multicenter study in China

Clinical randomized controlled trials of Gatifloxacin injection in the treatment of bacterial infections of lower respiratory tract and urinary tract

A Randomized Double-blind Control Clinical Study on Moxifloxacin for Treatment of Bacterial Skin Infections

A multi-centric randomized controlled trial of sequential intravenous moxifloxacin in comparison to cefoperazone-sulbactam for the treatment of acute biliary tract infection

A randomized, active-controlled, multicentre clinical trial to evaluate the efficacy and safety of oral sitafloxacin versus levofloxacin in Chinese adults with acute uncomplicated or complicated urinary tract infection

Clinical efficacy of ofloxacin and levofloxacin treatment on pelvic inflammatory disease

An Open-Label, Uncontrolled, Multicenter Study to Evaluate the Efficacy and Safety of Oral Levofloxacin 500 Mg Once Daily in Patients with Lower Respiratory Tract Infections or Urinary Tract Infections